Annual Accounts Payable
$2.20 B
-$399.00 M-15.33%
December 31, 2024
Summary
- As of February 6, 2025, TEVA annual accounts payable is $2.20 billion, with the most recent change of -$399.00 million (-15.33%) on December 31, 2024.
- During the last 3 years, TEVA annual accounts payable has risen by +$517.00 million (+30.66%).
- TEVA annual accounts payable is now -15.33% below its all-time high of $2.60 billion, reached on December 31, 2023.
Performance
TEVA Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Payable
$2.20 B
-$168.00 M-7.09%
December 31, 2024
Summary
- As of February 6, 2025, TEVA quarterly accounts payable is $2.20 billion, with the most recent change of -$168.00 million (-7.09%) on December 31, 2024.
- Over the past year, TEVA quarterly accounts payable has dropped by -$236.00 million (-9.68%).
- TEVA quarterly accounts payable is now -32.55% below its all-time high of $3.27 billion, reached on September 30, 2007.
Performance
TEVA Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Payable Formula
Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers
TEVA Accounts Payable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -15.3% | -9.7% |
| 3 y3 years | +30.7% | +15.9% |
| 5 y5 years | +28.2% | +25.5% |
TEVA Accounts Payable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -15.3% | +30.7% | -15.3% | +34.7% |
| 5 y | 5-year | -15.3% | +30.7% | -15.3% | +45.5% |
| alltime | all time | -15.3% | +3248.0% | -32.5% | +3248.0% |
Teva Pharmaceutical Industries Limited Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $2.20 B(-15.3%) | $2.20 B(-7.1%) |
| Sep 2024 | - | $2.37 B(+0.2%) |
| Jun 2024 | - | $2.37 B(-3.0%) |
| Mar 2024 | - | $2.44 B(-6.3%) |
| Dec 2023 | $2.60 B(+37.9%) | $2.60 B(+14.1%) |
| Sep 2023 | - | $2.28 B(-9.1%) |
| Jun 2023 | - | $2.51 B(+5.3%) |
| Mar 2023 | - | $2.38 B(+26.2%) |
| Dec 2022 | $1.89 B(+11.9%) | $1.89 B(+15.4%) |
| Sep 2022 | - | $1.64 B(-14.0%) |
| Jun 2022 | - | $1.90 B(+8.6%) |
| Mar 2022 | - | $1.75 B(+3.8%) |
| Dec 2021 | $1.69 B(-4.0%) | $1.69 B(+11.4%) |
| Sep 2021 | - | $1.51 B(-2.4%) |
| Jun 2021 | - | $1.55 B(-8.3%) |
| Mar 2021 | - | $1.69 B(-3.6%) |
| Dec 2020 | $1.76 B(+2.2%) | $1.76 B(+2.3%) |
| Sep 2020 | - | $1.72 B(+6.8%) |
| Jun 2020 | - | $1.61 B(-6.1%) |
| Mar 2020 | - | $1.71 B(-0.5%) |
| Dec 2019 | $1.72 B(-7.3%) | $1.72 B(+1.8%) |
| Sep 2019 | - | $1.69 B(-6.5%) |
| Jun 2019 | - | $1.81 B(+2.4%) |
| Mar 2019 | - | $1.76 B(-4.9%) |
| Dec 2018 | $1.85 B(-10.4%) | $1.85 B(+14.0%) |
| Sep 2018 | - | $1.63 B(-8.6%) |
| Jun 2018 | - | $1.78 B(-7.8%) |
| Mar 2018 | - | $1.93 B(-6.8%) |
| Dec 2017 | $2.07 B(-4.1%) | $2.07 B(-12.7%) |
| Sep 2017 | - | $2.37 B(+4.0%) |
| Jun 2017 | - | $2.28 B(-4.2%) |
| Mar 2017 | - | $2.38 B(+10.2%) |
| Dec 2016 | $2.16 B(+12.5%) | $2.16 B(+12.5%) |
| Dec 2015 | $1.92 B(+38.7%) | $1.92 B(-12.4%) |
| Sep 2009 | - | $2.19 B(+2.8%) |
| Jun 2009 | - | $2.13 B(+3.3%) |
| Mar 2009 | - | $2.06 B(+29.6%) |
| Sep 2008 | - | $1.59 B(+5.6%) |
| Jun 2008 | - | $1.50 B(+10.6%) |
| Mar 2008 | - | $1.36 B(-1.6%) |
| Dec 2007 | $1.38 B | $1.38 B(-57.7%) |
| Sep 2007 | - | $3.27 B(+1.6%) |
| Jun 2007 | - | $3.21 B(+3.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2007 | - | $3.12 B(+22.0%) |
| Dec 2006 | $2.56 B(+35.6%) | $2.56 B(-20.3%) |
| Sep 2006 | - | $3.21 B(+9.2%) |
| Jun 2006 | - | $2.94 B(+12.1%) |
| Mar 2006 | - | $2.62 B(+39.0%) |
| Dec 2005 | $1.89 B(+14.7%) | $1.89 B(+6.1%) |
| Sep 2005 | - | $1.78 B(+6.4%) |
| Jun 2005 | - | $1.67 B(-0.9%) |
| Mar 2005 | - | $1.68 B(+2.5%) |
| Dec 2004 | $1.64 B(+56.5%) | $1.64 B(+8.0%) |
| Sep 2004 | - | $1.52 B(+9.1%) |
| Jun 2004 | - | $1.39 B(+3.7%) |
| Mar 2004 | - | $1.34 B(+27.9%) |
| Dec 2003 | $1.05 B(+33.7%) | $1.05 B(+9.9%) |
| Sep 2003 | - | $956.20 M(+1.6%) |
| Jun 2003 | - | $941.60 M(+10.8%) |
| Mar 2003 | - | $849.60 M(+8.1%) |
| Dec 2002 | $785.70 M(+47.8%) | $785.70 M(+10.7%) |
| Sep 2002 | - | $709.90 M(+5.9%) |
| Jun 2002 | - | $670.10 M(+19.9%) |
| Mar 2002 | - | $558.90 M(+5.1%) |
| Dec 2001 | $531.60 M(+228.5%) | $531.60 M(+1.4%) |
| Sep 2001 | - | $524.10 M(+2.8%) |
| Jun 2001 | - | $509.77 M(+4.5%) |
| Mar 2001 | - | $487.78 M(+201.4%) |
| Dec 2000 | $161.84 M(+41.4%) | $161.84 M(-56.9%) |
| Jun 2000 | - | $375.91 M(+52.6%) |
| Mar 2000 | - | $246.32 M(+115.2%) |
| Dec 1999 | $114.45 M(-45.1%) | $114.45 M(-53.6%) |
| Sep 1999 | - | $246.60 M(+22.9%) |
| Jun 1999 | - | $200.60 M(+8.8%) |
| Mar 1999 | - | $184.30 M(-11.6%) |
| Dec 1998 | $208.60 M(+14.4%) | $208.60 M(-0.1%) |
| Sep 1998 | - | $208.90 M(+29.6%) |
| Jun 1998 | - | $161.20 M(-14.8%) |
| Mar 1998 | - | $189.10 M(+3.7%) |
| Dec 1997 | $182.40 M(+1.1%) | $182.40 M(+1.1%) |
| Dec 1996 | $180.50 M(-1.6%) | $180.50 M(-1.6%) |
| Dec 1995 | $183.50 M(+80.6%) | $183.50 M(+80.6%) |
| Dec 1994 | $101.60 M(+0.1%) | $101.60 M(+0.1%) |
| Dec 1993 | $101.50 M(+38.9%) | $101.50 M(+38.9%) |
| Dec 1992 | $73.10 M(+11.1%) | $73.10 M(+11.1%) |
| Dec 1991 | $65.80 M | $65.80 M |
FAQ
- What is Teva Pharmaceutical Industries Limited annual accounts payable?
- What is the all time high annual accounts payable for Teva Pharmaceutical Industries Limited?
- What is Teva Pharmaceutical Industries Limited annual accounts payable year-on-year change?
- What is Teva Pharmaceutical Industries Limited quarterly accounts payable?
- What is the all time high quarterly accounts payable for Teva Pharmaceutical Industries Limited?
- What is Teva Pharmaceutical Industries Limited quarterly accounts payable year-on-year change?
What is Teva Pharmaceutical Industries Limited annual accounts payable?
The current annual accounts payable of TEVA is $2.20 B
What is the all time high annual accounts payable for Teva Pharmaceutical Industries Limited?
Teva Pharmaceutical Industries Limited all-time high annual accounts payable is $2.60 B
What is Teva Pharmaceutical Industries Limited annual accounts payable year-on-year change?
Over the past year, TEVA annual accounts payable has changed by -$399.00 M (-15.33%)
What is Teva Pharmaceutical Industries Limited quarterly accounts payable?
The current quarterly accounts payable of TEVA is $2.20 B
What is the all time high quarterly accounts payable for Teva Pharmaceutical Industries Limited?
Teva Pharmaceutical Industries Limited all-time high quarterly accounts payable is $3.27 B
What is Teva Pharmaceutical Industries Limited quarterly accounts payable year-on-year change?
Over the past year, TEVA quarterly accounts payable has changed by -$236.00 M (-9.68%)